The evidence supports recalibrating cervical cancer screening beyond age 65 years using risk-informed HPV-based strategies. Targeted catch-up testing and well-designed self-sampling pathways may improve coverage and detection of clinically relevant disease in select older populations.
Ebru Zülfikaroğlu (Thu,) studied this question.